Published ahead of print on February 6, 2009, doi:10.1164/rccm.200807-1125OC
© 2009 American Thoracic Society doi: 10.1164/rccm.200807-1125OC
Kinetics of Soluble Mesothelin in Patients with Malignant Pleural Mesothelioma during Treatment1 INSERM Unit 774, Institut Pasteur of Lille, Lille, France; 2 Department of Pulmonary Diseases, University of Medicine and Pharmacy, Iasi, Romania; 3 Thoracic Oncology Department, CHRU of Lille, University of Lille II, Lille, France; 4 Thoracic Oncology Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania; and 5 Department of Thoracic Surgery, CHRU of Lille, University of Lille II, Lille, France Correspondence and requests for reprints should be addressed to Arnaud Scherpereel, M.D., Ph.D., Pulmonary and Thoracic Oncology Department, Hopital Calmette, CHRU of Lille, 59037 Lille cedex, France. E-mail: a-scherpereel{at}chru-lille.fr Rationale: Previous data suggested that serum levels of soluble mesothelin (SM) are related to tumor size and may have prognostic significance in malignant pleural mesothelioma (MPM). Objectives: We tested the hypothesis that this marker could also be useful for monitoring response to treatment. Methods: Serial measurements of SM were determined in 40 patients diagnosed with MPM and subjected to gene-transfer therapy using intrapleural infusion of an adenoviral vector expressing human IFN-β or conventional treatment (mainly chemotherapy). Measurements and Main Results: In patients with baseline SM levels greater than 1 nM/L and disease progression after therapy, SM levels increased by 2.1 nM/L at two, 5.2 nM/L at four and 1.3 nM/L at 6 months. Patients with initial SM below 1 nM/L had a similar but more moderate increase of SM over time. Patients who responded to treatment or were considered stable had an initial small decrease of SM followed by a return to baseline values after 6 months of follow-up. In patients with baseline SM levels greater than 1 nM/L, increasing levels were associated with a significantly shorter median survival than in patients with stable or decreasing SM levels (4.4 vs. 27.7 months; P = 0.012). Conclusions: Increasing serum levels of SM were associated with disease progression and worse outcome, whereas stable or decreasing values suggested response to treatment. If confirmed in larger series, SM could be used to monitor patients with malignant pleural mesothelioma under treatment.
Key Words: pleura • neoplasm • prognosis • marker
This article has been cited by other articles:
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
